Mushroom boardroom: Why some execs are using psychedelics to get through the workday
This is a preview of a story that was initially published on our sister site, WorkLife, which covers the future of the workplace.
After his father died in 2018, Paul Marlow struggled with fear, anxiety and depression. That’s when he turned to microdosing psychedelics as a remedy — and he hasn’t looked back.
Microdosing, he said, helps him focus at work. As the pandemic persists, many who are looking for a jolt of motivation, inspiration or medication are turning to microdosing — that is, ingesting small amounts of psychedelic drugs to combat mental health issues and enhance creativity, productivity and physical well-being. Read the full story on WorkLife.
More in Marketing
Who owns the creative brief? Brands and creators are renegotiating the relationship
Brands are moving creators beyond sponsored posts and into the creative process, reshaping who influences marketing decisions.
Future of Marketing Briefing: Media measurement is becoming an asset in boardroom theater
Major advertisers spent their quarterly earnings calls talking up media effectiveness efforts to analysts and shareholders this week. It suggests a shift in the way C-suites consider ad spend.
Nike, Lululemon hit with lawsuits alleging deceptive ‘phantom discounts’
In recent weeks, major global brands have been the subject of lawsuits alleging deceptive pricing strategies.